FBP1 and neoplasm: Similarly, FBP1 was proven to inhibit tumor progression in cholangiocarcinoma (CCA) (Zhao et al., 2018), prostate cancer (PCA) (Zhang et al., 2019), and lung adenocarcinoma (LUAD) (Li L. et al., 2020).